Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
1.
Thromb Haemost ; 86(3): 739-45, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11583303

RÉSUMÉ

The direct fibrinolytic enzyme, plasmin, was compared with tissue plasminogen activator (TPA) in rabbit models of local thrombolysis and fibrinolytic hemorrhage. Plasmin was produced by solid-phase urokinase activation of plasminogen and purified on benzamidine Sepharose. Applied as an intra-arterial infusion into the thrombosed abdominal aorta under conditions of unimpeded blood flow, plasmin (4 mg/kg) and TPA (2 mg/kg) achieved equivalent clot dissolution and flow restoration. Using the model of restricted blood flow into the thrombosed aorta, which limits local plasminogen supply, plasmin was superior to TPA in clot lysis and vascular reperfusion. Using similar dosages of plasmin (2 or 4 mg/kg) and TPA (1 or 2 mg/kg) in the earpuncture rebleed model. TPA induced rebleeding in a dose-dependent manner from prior puncture sites in 9 of 10 animals, while none of the 10 animals exposed to plasmin rebled from these sites. These results suggest that plasmin is an effective, unique thrombolytic agent, distinguished from the plasminogen activators in current usage by its striking safety profile.


Sujet(s)
Maladies de l'aorte/traitement médicamenteux , Fibrinolysine/usage thérapeutique , Fibrinolyse/effets des médicaments et des substances chimiques , Fibrinolytiques/usage thérapeutique , Hémorragie/prévention et contrôle , Traitement thrombolytique , Thrombose/traitement médicamenteux , Activateur tissulaire du plasminogène/usage thérapeutique , Animaux , Aorte abdominale , Relation dose-effet des médicaments , Évaluation préclinique de médicament , Oreille , Fibrinolysine/pharmacologie , Fibrinolytiques/pharmacologie , Hémorragie/induit chimiquement , Perfusions artérielles , Lapins , Récidive , Sécurité , Traitement thrombolytique/effets indésirables , Activateur tissulaire du plasminogène/pharmacologie
2.
Thromb Haemost ; 82(5): 1412-6, 1999 Nov.
Article de Anglais | MEDLINE | ID: mdl-10595629

RÉSUMÉ

Our previous prospective study of post-infarction patients described a strong and significant association of increased plasma D-dimer concentrations in those who experienced a subsequent coronary death or non-fatal myocardial infarction. In the present study, we compare results on stored plasma obtained two months after the index myocardial infarction from 1,038 patients of this trial, using a simple automated latex agglutination (LA) assay in parallel with the standard ELISA test. Results show a somewhat higher mean value for the LA assay (702+/-1092 vs. 638+/-986 ng/ml, p = 0.0002), a strong linear correlation of the two assays (r = 0.86) and 88% agreement for values below 500 ng/ml by the ELISA test. D-dimer concentrations determined by each assay were highly correlated in patients with subsequent coronary artery events (p = 0.93) and quartile values for both the LA and ELISA were equally predictive of such events (p = 0.003 and p = 0.001, respectively). This is the first demonstration that a latex agglutination assay for D-dimer can be used to assess the prognostic risk of recurrent coronary thrombotic disease after myocardial infarction


Sujet(s)
Test ELISA/méthodes , Produits de dégradation de la fibrine et du fibrinogène/analyse , Tests au latex/méthodes , Infarctus du myocarde/sang , Adulte , Automatisation , Études d'évaluation comme sujet , Humains , Pronostic , Récidive , Études rétrospectives
3.
Thromb Haemost ; 82(1): 145-8, 1999 Jul.
Article de Anglais | MEDLINE | ID: mdl-10456469

RÉSUMÉ

A soluble fibrin (SF) preparation has been developed as a potential standard by the Scientific and Standardization Committee for use in assays evaluating in vitro preparations and patient plasma samples. The SF standard was prepared by reaction of factor XIII-free fibrinogen with thrombin, followed by neutralization with hirudin and solubilization of the fibrin in acetic acid. As characterized by SDS-PAGE, the polypeptide chain structure shows the anticipated loss of fibrinopeptides and lack of gamma or alpha chain crosslinking. The standard was added to pooled normal plasma at concentrations from 12.5 microg/ml to 340 microg/ml and tested with four commercially available assays based on immunologic reactions using ELISA or latex agglutination or on t-PA cofactor activity for plasminogen to plasmin conversion. Absolute "soluble fibrin" concentrations were calculated using the manufacturers' calibrators and showed distinct dose-response relationships for each assay. Expression of the results following log-transformation produced a series of parallel lines, indicating that this SF preparation can serve as a standard, effectively normalizing the disparate proprietary internal calibrators currently used for each assay.


Sujet(s)
Fibrine/normes , Rapport international normalisé , Dosage biologique , Relation dose-effet des médicaments , Fibrine/analyse , Humains , Dosage immunologique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...